Jean George - Net Worth and Insider Trading

Jean George Net Worth

The estimated net worth of Jean George is at least $687,213 dollars as of 2024-11-13. Jean George is the Director of Acceleron Pharma Inc and owns about 3,750 shares of Acceleron Pharma Inc (XLRN) stock worth over $670,313. Jean George is the Director of Astria Therapeutics Inc and owns about 1,513 shares of Astria Therapeutics Inc (ATXS) stock worth over $16,900. Jean George is also the Director of ZELTIQ Aesthetics Inc and owns about 0 shares of ZELTIQ Aesthetics Inc (ZLTQ) stock worth over $0. Details can be seen in Jean George's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jean George has not made any transactions after 2019-06-28 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Jean George

Jean George Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jean George owns 8 companies in total, including ALX Oncology Holdings Inc (ALXO) , Calithera Biosciences Inc (CALA) , and Acceleron Pharma Inc (XLRN) among others .

Click here to see the complete history of Jean George’s form 4 insider trades.

Insider Ownership Summary of Jean George

Ticker	Comapny	Transaction Date	Type of Owner
ALXO	ALX Oncology Holdings Inc	2020-07-16	10 percent owner
CALA	Calithera Biosciences Inc	2016-06-14	director & 10 percent owner
XLRN	Acceleron Pharma Inc	2020-01-22	director
		2015-06-30	director & 10 percent owner
		2015-07-22	director
		2013-05-28	director
		2021-06-17	director
		2021-02-05	director & 10 percent owner

Jean George Latest Holdings Summary

Jean George currently owns a total of 3 stocks. Among these stocks, Jean George owns 3,750 shares of Acceleron Pharma Inc (XLRN) as of June 28, 2019, with a value of $670,313 and a weighting of 97.54%. Jean George owns 1,513 shares of Astria Therapeutics Inc (ATXS) as of June 30, 2015, with a value of $16,900 and a weighting of 2.46%. Jean George also owns 0 shares of ZELTIQ Aesthetics Inc (ZLTQ) as of November 3, 2014, with a value of $0 and a weighting of 0%.

Latest Holdings of Jean George

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
XLRN	Acceleron Pharma Inc	2019-06-28	3,750	178.75	670,313
ATXS	Astria Therapeutics Inc	2015-06-30	1,513	11.17	16,900
ZLTQ	ZELTIQ Aesthetics Inc	2014-11-03	0	56.48	0

Holding Weightings of Jean George

Jean George Form 4 Trading Tracker

According to the SEC Form 4 filings, Jean George has made a total of 0 transactions in Acceleron Pharma Inc (XLRN) over the past 5 years. The most-recent trade in Acceleron Pharma Inc is the sale of 37,500 shares on June 28, 2019, which brought Jean George around $1 Million.

According to the SEC Form 4 filings, Jean George has made a total of 0 transactions in Astria Therapeutics Inc (ATXS) over the past 5 years. The most-recent trade in Astria Therapeutics Inc is the acquisition of 4,313 shares on June 30, 2015, which cost Jean George around $3 Million.

According to the SEC Form 4 filings, Jean George has made a total of 0 transactions in ZELTIQ Aesthetics Inc (ZLTQ) over the past 5 years. The most-recent trade in ZELTIQ Aesthetics Inc is the sale of 17,483 shares on November 3, 2014, which brought Jean George around $439,697.

Insider Trading History of Jean George

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jean George Trading Performance

GuruFocus tracks the stock performance after each of Jean George's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jean George is -33.74%. GuruFocus also compares Jean George's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jean George within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jean George's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jean George

Average Return

Average return per transaction

Outperforming Transactions

0 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	14.33
Relative Return to S&P 500(%)	12.12

Jean George Ownership Network

Ownership Network List of Jean George

No Data

Ownership Network Relation of Jean George

Jean George Owned Company Details

What does ALX Oncology Holdings Inc do?

Who are the key executives at ALX Oncology Holdings Inc?

Jean George is the 10 percent owner of ALX Oncology Holdings Inc. Other key executives at ALX Oncology Holdings Inc include VP & Finance and CAO Shelly Pinto , Chief Medical Officer Sophia Randolph , and director & President and CEO Jaume Pons .

ALX Oncology Holdings Inc (ALXO) Insider Trades Summary

Over the past 18 months, Jean George made no insider transaction in ALX Oncology Holdings Inc (ALXO). Other recent insider transactions involving ALX Oncology Holdings Inc (ALXO) include a net sale of 145,903 shares made by Jaume Pons , a net sale of 14,288 shares made by Shelly Pinto , and a net sale of 18,243 shares made by Sophia Randolph .

In summary, during the past 3 months, insiders sold 3,866 shares of ALX Oncology Holdings Inc (ALXO) in total and bought 0 shares, with a net sale of 3,866 shares. During the past 18 months, 179,321 shares of ALX Oncology Holdings Inc (ALXO) were sold and 28,400 shares were bought by its insiders, resulting in a net sale of 150,921 shares.

ALX Oncology Holdings Inc (ALXO)'s detailed insider trading history can be found in Insider Trading Tracker table.

ALX Oncology Holdings Inc Insider Transactions

No Available Data

What does Calithera Biosciences Inc do?

Who are the key executives at Calithera Biosciences Inc?

Jean George is the director & 10 percent owner of Calithera Biosciences Inc. Other key executives at Calithera Biosciences Inc include director & 10 percent owner Deepika Pakianathan , 10 percent owner Takeda Ventures, Inc. , and SR. VP & CLINICAL DEVELOPMENT Keith Orford .

Calithera Biosciences Inc (CALA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Calithera Biosciences Inc (CALA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Calithera Biosciences Inc (CALA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Calithera Biosciences Inc (CALA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Calithera Biosciences Inc Insider Transactions

No Available Data

What does Acceleron Pharma Inc do?

Who are the key executives at Acceleron Pharma Inc?

Jean George is the director of Acceleron Pharma Inc. Other key executives at Acceleron Pharma Inc include EVP & Chief Commercial Officer Sujay Kango , SVP & CFO and Treasurer Kevin F Mclaughlin , and SVP & General Counsel and Sec. Adam M Veness .

Acceleron Pharma Inc (XLRN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Acceleron Pharma Inc (XLRN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Acceleron Pharma Inc (XLRN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Acceleron Pharma Inc (XLRN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Acceleron Pharma Inc Insider Transactions

No Available Data

What does Astria Therapeutics Inc do?

Who are the key executives at Astria Therapeutics Inc?

Jean George is the director & 10 percent owner of Astria Therapeutics Inc. Other key executives at Astria Therapeutics Inc include Chief Medical Officer Christopher Morabito , director & 10 percent owner Perceptive Life Sciences Master Fund Ltd , and Chief Business Officer Andrea Matthews .

Astria Therapeutics Inc (ATXS) Insider Trades Summary

Over the past 18 months, Jean George made no insider transaction in Astria Therapeutics Inc (ATXS). Other recent insider transactions involving Astria Therapeutics Inc (ATXS) include a net purchase of 4,295,958 shares made by Perceptive Life Sciences Master Fund Ltd , and a net sale of 20,000 shares made by Christopher Morabito .

In summary, during the past 3 months, insiders sold 0 shares of Astria Therapeutics Inc (ATXS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 20,000 shares of Astria Therapeutics Inc (ATXS) were sold and 4,295,958 shares were bought by its insiders, resulting in a net purchase of 4,275,958 shares.

Astria Therapeutics Inc (ATXS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Astria Therapeutics Inc Insider Transactions

No Available Data

What does ZELTIQ Aesthetics Inc do?

Who are the key executives at ZELTIQ Aesthetics Inc?

Jean George is the director of ZELTIQ Aesthetics Inc. Other key executives at ZELTIQ Aesthetics Inc include director & 10 percent owner Andrew N Schiff , SVP & Research and Development Bradley Hauser , and SVP of Global Marketing Danika R Harrison .

ZELTIQ Aesthetics Inc (ZLTQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of ZELTIQ Aesthetics Inc (ZLTQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ZELTIQ Aesthetics Inc (ZLTQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

ZELTIQ Aesthetics Inc (ZLTQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

ZELTIQ Aesthetics Inc Insider Transactions

No Available Data

What does Portola Pharmaceuticals Inc do?

Who are the key executives at Portola Pharmaceuticals Inc?

Jean George is the director of Portola Pharmaceuticals Inc. Other key executives at Portola Pharmaceuticals Inc include EVP & General Counsel John B Moriarty , EVP and CFO Mardi Dier , and EVP & CMO Rajiv Patni .

Portola Pharmaceuticals Inc (PTLA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Portola Pharmaceuticals Inc (PTLA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Portola Pharmaceuticals Inc (PTLA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Portola Pharmaceuticals Inc (PTLA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Portola Pharmaceuticals Inc Insider Transactions

No Available Data

What does Cyteir Therapeutics Inc do?

Who are the key executives at Cyteir Therapeutics Inc?

Jean George is the director of Cyteir Therapeutics Inc. Other key executives at Cyteir Therapeutics Inc include 10 percent owner Novo Holdings A/s , General Counsel Adam M Veness , and 10 percent owner Droia Invest Ii Scsp .

Cyteir Therapeutics Inc (CYTT) Insider Trades Summary

Over the past 18 months, Jean George made no insider transaction in Cyteir Therapeutics Inc (CYTT). Other recent insider transactions involving Cyteir Therapeutics Inc (CYTT) include a net sale of 418,277 shares made by Novo Holdings A/s , and a net purchase of 170,589 shares made by Braden Michael Leonard .

In summary, during the past 3 months, insiders sold 0 shares of Cyteir Therapeutics Inc (CYTT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 418,277 shares of Cyteir Therapeutics Inc (CYTT) were sold and 170,589 shares were bought by its insiders, resulting in a net sale of 247,688 shares.

Cyteir Therapeutics Inc (CYTT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cyteir Therapeutics Inc Insider Transactions

No Available Data

What does Disc Medicine Inc do?

Who are the key executives at Disc Medicine Inc?

Jean George is the director & 10 percent owner of Disc Medicine Inc. Other key executives at Disc Medicine Inc include Chief Medical Officer William Jacob Savage , director & 10 percent owner Orbimed Advisors Llc , and director & 10 percent owner Mona Ashiya .

Disc Medicine Inc (IRON) Insider Trades Summary

Over the past 18 months, Jean George made no insider transaction in Disc Medicine Inc (IRON). Other recent insider transactions involving Disc Medicine Inc (IRON) include a net sale of 48,126 shares made by William Richard White , a net sale of 75,429 shares made by Kevin Bitterman , and a net sale of 1,106,612 shares made by Atlas Venture Fund X, L.p. .

In summary, during the past 3 months, insiders sold 12,495 shares of Disc Medicine Inc (IRON) in total and bought 0 shares, with a net sale of 12,495 shares. During the past 18 months, 3,914,721 shares of Disc Medicine Inc (IRON) were sold and 388,891 shares were bought by its insiders, resulting in a net sale of 3,525,830 shares.

Disc Medicine Inc (IRON)'s detailed insider trading history can be found in Insider Trading Tracker table.

Disc Medicine Inc Insider Transactions

No Available Data

Jean George Mailing Address

Above is the net worth, insider trading, and ownership report for Jean George. You might contact Jean George via mailing address: Critical Therapeutics Inc, 60 Westview Street, Lexington Ma 02421.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.